A life science marketing agency sells to a narrow, technical audience on behalf of companies whose claims are regulated: pharmaceutical and biotech developers, medical device makers, contract research and manufacturing organizations, diagnostics firms and lab tool suppliers. The buyers are scientists, procurement teams and clinicians, the sales cycles run in quarters rather than weeks, and a careless sentence in a campaign can become a regulatory problem rather than a marketing one. That combination is why generalist agencies struggle here and why specialist retainers cost more. This page covers what the work involves, the constraints that shape it, and what to check before you appoint anyone.
What the specialists actually do
The deliverables look familiar until you inspect them. Positioning work has to survive scrutiny by people who read primary literature, so it leans on data rather than adjectives. Content work means application notes, technical briefs, poster and abstract support, webinars with named investigators, and case studies that describe method as well as outcome, which requires writers who can read a protocol. Demand work is unusually channel-specific: conference presence, society publications and targeted trade media often outperform broad paid search because the addressable audience is small and identifiable. Search still matters, because a scientist evaluating a reagent or an instrument searches like anyone else, but the winning page is the one that answers a technical question completely rather than the one that repeats a keyword. The tell of a genuine specialist is the staff list: people with laboratory or clinical backgrounds writing the content, not just editing it.
The rules that shape every claim
Marketing in this sector runs inside two regulatory perimeters at once. For prescription drug promotion, the FDA's guidance on drug advertising states that advertisements must not be false or misleading and must present a fair balance of information about risks and benefits, and product claim advertisements must name the drug and disclose its risks. For health-related claims generally, the FTC's health products compliance guidance requires that objective claims be supported by competent and reliable scientific evidence, and it is clear that a disclaimer does not rescue a claim the underlying evidence cannot support. An agency working in this sector should be able to describe how its copy passes medical, legal and regulatory review inside a client organization, and should have worked to that cadence before. If a candidate treats review as an obstacle rather than the operating condition, the retainer will run late and the claims will run loose.
How to vet a candidate agency
Ask for three things and read them carefully. First, named clients in an adjacent modality or market, because a firm that markets lab consumables is not automatically fluent in clinical-stage biotech communications. Second, samples of technical writing produced by the agency, and the name of the person who wrote them, so you know whether the science was written by a scientist or dressed by a copywriter. Third, a description of how the agency handles the review cycle: who assembles the reference pack, how claims are annotated, and how many rounds a typical piece takes. Then check the commercial shape: whether the retainer includes editorial capacity or bills it separately, whether media and production are marked up, and who owns the assets when the relationship ends. When the shortlist reaches a decision, the same evidence test applies to buying digital marketing and SEO services as it does to appointing a scientific writer.
Measurement that means something here
Lead counts are a poor scoreboard in a market where a target account list might be a few hundred organizations worldwide. Better instruments exist: coverage of the target account list, engagement from named accounts, sample or demo requests, quotes issued, and time from first touch to a qualified technical conversation. Agree the definitions before the first invoice, because a life science funnel that reports form fills will flatter a campaign that reached nobody who buys. Attribution is genuinely hard here, so accept honest partial evidence, such as self-reported source at enquiry combined with account-level engagement, rather than a dashboard that claims certainty it cannot have. An agency that argues for the harder, truer metric at pitch stage is telling you how it will report a bad quarter.
Questions people ask about life science marketing agency
Why do life science agencies cost more than generalists?
Because the writing requires technical training, the review cycle is longer, and the claims carry regulatory exposure. You are paying for staff who can read a protocol and for the process that keeps promotional copy inside the limits the FDA and FTC set for health-related claims.
Can an agency make efficacy claims for our product?
Only what your evidence supports and your regulatory review approves. FDA guidance on drug advertising requires that ads not be false or misleading and that risk and benefit information be fairly balanced, and the FTC's health products compliance guidance requires competent and reliable scientific evidence behind objective claims.
Does SEO matter when the audience is a few hundred accounts?
Yes, but as a technical answering exercise rather than a volume play. Scientists search for methods, compatibility, specifications and troubleshooting. Pages that answer those questions completely earn the visit that a conference badge cannot, and they keep earning it between events.
What should be in the contract?
Named staff on the account, ownership of copy, data and creative assets, a defined review workflow with turnaround expectations, treatment of media and production markups, and an exit clause that returns work in editable formats. Ambiguity on asset ownership is the most common and most expensive omission.